title: Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds.
authors.forename: M C
authors.initials: MC
authors.lastname: Lazanas
authors.forename: G A
authors.initials: GA
authors.lastname: Tsekes
authors.forename: S
authors.initials: S
authors.lastname: Papandreou
authors.forename: N
authors.initials: N
authors.lastname: Harhalakis
authors.forename: A
authors.initials: A
authors.lastname: Scandali
authors.forename: E
authors.initials: E
authors.lastname: Nikiforakis
authors.forename: G
authors.initials: G
authors.lastname: Saroglou
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D004304:Dosage Forms; D005260:Female; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*
chemical_list: D004304:Dosage Forms; D008081:Liposomes; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B